默沙东-话题@MedSci

#默沙东#

121篇内容 | 2089人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259997, encodeId=a272125999e8a, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=33, createdTime=2022-04-04, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259996, encodeId=96da1259996f4, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=重磅新药！默沙东「来特莫韦片」在中国获批，用于巨细胞病毒的预防性治疗, objectType=article, longId=293459, objectId=7059293459e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7059293459e3, replyNumber=0, likeNumber=42, createdTime=2022-01-07, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7059293459e3, moduleTitle=重磅新药！默沙东「来特莫韦片」在中国获批，用于巨细胞病毒的预防性治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7059293459e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259995, encodeId=fe79125999541, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=NEJM：默沙东ROR1 ADC展现淋巴瘤治疗的潜力, objectType=article, longId=221214, objectId=b11722121458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b11722121458, replyNumber=0, likeNumber=39, createdTime=2021-11-30, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b11722121458, moduleTitle=NEJM：默沙东ROR1 ADC展现淋巴瘤治疗的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b11722121458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259994, encodeId=abf81259994d2, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=跌破眼球！默沙东新冠病毒口服药有效率降至30%！, objectType=article, longId=221158, objectId=828022115871, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=828022115871, replyNumber=0, likeNumber=36, createdTime=2021-11-28, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=828022115871, moduleTitle=跌破眼球！默沙东新冠病毒口服药有效率降至30%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=828022115871)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259992, encodeId=8512125999258, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=英国批准默沙东新冠口服药物molnupiravir，开创新冠治疗的新时代！, objectType=article, longId=219813, objectId=f9052198134a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9052198134a, replyNumber=0, likeNumber=0, createdTime=2021-11-06, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9052198134a, moduleTitle=英国批准默沙东新冠口服药物molnupiravir，开创新冠治疗的新时代！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9052198134a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259991, encodeId=62cd125999155, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=2021年10月26日简报：湖北、浙江、海南等地启动3-11岁人群新冠病毒疫苗接种；欧洲药品管理局开始滚动审查默沙东新冠口服药物, objectType=article, longId=219276, objectId=11432192e670, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11432192e670, replyNumber=0, likeNumber=39, createdTime=2021-10-27, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11432192e670, moduleTitle=2021年10月26日简报：湖北、浙江、海南等地启动3-11岁人群新冠病毒疫苗接种；欧洲药品管理局开始滚动审查默沙东新冠口服药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11432192e670)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259990, encodeId=68c3125999052, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东治疗新冠肺炎口服特效药Molnupiravir取得良好效果，降低住院或死亡率50%，未来可能是治疗新冠的决定性药物之一, objectType=article, longId=218060, objectId=511121806096, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=511121806096, replyNumber=0, likeNumber=51, createdTime=2021-10-04, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=511121806096, moduleTitle=默沙东治疗新冠肺炎口服特效药Molnupiravir取得良好效果，降低住院或死亡率50%，未来可能是治疗新冠的决定性药物之一, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=511121806096)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259989, encodeId=c4ba125998926, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东以110亿美元收购Accelron接近完成，押注呼吸和血液疾病领域, objectType=article, longId=217964, objectId=9dba21e96483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dba21e96483, replyNumber=0, likeNumber=36, createdTime=2021-10-02, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dba21e96483, moduleTitle=默沙东以110亿美元收购Accelron接近完成，押注呼吸和血液疾病领域, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dba21e96483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259988, encodeId=b61d125998859, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东多拉韦林上市有望帮助HIV感染者应对血脂异常问题, objectType=article, longId=213113, objectId=d71d2131132d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d71d2131132d, replyNumber=0, likeNumber=37, createdTime=2021-06-25, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d71d2131132d, moduleTitle=默沙东多拉韦林上市有望帮助HIV感染者应对血脂异常问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d71d2131132d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259993, encodeId=e1d81259993a9, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东中国研发中心十年：守正出奇, objectType=article, longId=211394, objectId=7e6a2113948a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e6a2113948a, replyNumber=0, likeNumber=27, createdTime=2021-05-17, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e6a2113948a, moduleTitle=默沙东中国研发中心十年：守正出奇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e6a2113948a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259987, encodeId=f435125998ec0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东联合Surface开展联合疗法研究，或将改善K药耐药性, objectType=article, longId=209545, objectId=c8ee20954549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ee20954549, replyNumber=0, likeNumber=35, createdTime=2021-04-05, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ee20954549, moduleTitle=默沙东联合Surface开展联合疗法研究，或将改善K药耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ee20954549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259986, encodeId=42831259986ee, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=HIV领域迎来强强联手，默沙东和吉利德合作开发长效方案, objectType=article, longId=209541, objectId=6ca5209541e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ca5209541e8, replyNumber=0, likeNumber=36, createdTime=2021-04-05, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ca5209541e8, moduleTitle=HIV领域迎来强强联手，默沙东和吉利德合作开发长效方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ca5209541e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259985, encodeId=c2ec125998564, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东在美国自主撤回Keytruda治疗转移性小细胞肺癌适应症, objectType=article, longId=208134, objectId=f8462081345b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8462081345b, replyNumber=0, likeNumber=48, createdTime=2021-03-09, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8462081345b, moduleTitle=默沙东在美国自主撤回Keytruda治疗转移性小细胞肺癌适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8462081345b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259984, encodeId=a5ad125998497, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东收购华人研发新冠肺炎创新药物，有望成为新冠重症特效药物, objectType=article, longId=207352, objectId=186420e352dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=186420e352dd, replyNumber=0, likeNumber=35, createdTime=2021-02-21, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=186420e352dd, moduleTitle=默沙东收购华人研发新冠肺炎创新药物，有望成为新冠重症特效药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=186420e352dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259983, encodeId=bbb612599830d, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东Keytruda治疗三阴性乳腺癌扩大标签申请未能获得FDA支持, objectType=article, longId=207159, objectId=3efa20e159a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3efa20e159a6, replyNumber=0, likeNumber=31, createdTime=2021-02-17, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3efa20e159a6, moduleTitle=默沙东Keytruda治疗三阴性乳腺癌扩大标签申请未能获得FDA支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3efa20e159a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259982, encodeId=e6731259982c5, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东10亿美元豪掷T细胞接合剂免疫疗法（TCE）, objectType=article, longId=204909, objectId=313b20490921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313b20490921, replyNumber=0, likeNumber=37, createdTime=2020-12-28, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313b20490921, moduleTitle=默沙东10亿美元豪掷T细胞接合剂免疫疗法（TCE）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313b20490921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259981, encodeId=8754125998159, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=丁香园与默沙东等疫苗巨头共建疫苗服务平台正式布局“互联网+疫苗”领域, objectType=article, longId=204157, objectId=3c3a20415e12, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c3a20415e12, replyNumber=0, likeNumber=0, createdTime=2020-12-07, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c3a20415e12, moduleTitle=丁香园与默沙东等疫苗巨头共建疫苗服务平台正式布局“互联网+疫苗”领域, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c3a20415e12)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259980, encodeId=f84e125998064, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东HIV领域重磅新药沛卓（多拉韦林）在华获批，血脂控制获益显著, objectType=article, longId=204113, objectId=eef420411373, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eef420411373, replyNumber=0, likeNumber=58, createdTime=2020-12-05, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eef420411373, moduleTitle=默沙东HIV领域重磅新药沛卓（多拉韦林）在华获批，血脂控制获益显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eef420411373)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259979, encodeId=d1d812599e93a, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东多拉韦林在中国获批上市, objectType=article, longId=203937, objectId=1ac120393ea6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ac120393ea6, replyNumber=0, likeNumber=40, createdTime=2020-12-02, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ac120393ea6, moduleTitle=默沙东多拉韦林在中国获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ac120393ea6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259977, encodeId=104a12599e723, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=随着抗菌素耐药性加剧，默沙东的新型抗生素组合Recarbrio在英国上市, objectType=article, longId=203565, objectId=f49420356502, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f49420356502, replyNumber=0, likeNumber=45, createdTime=2020-11-21, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f49420356502, moduleTitle=随着抗菌素耐药性加剧，默沙东的新型抗生素组合Recarbrio在英国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f49420356502)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

默沙东

2020-05-29

yese (审核中...)

前往app查看评论内容

#默沙东#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2022-04-04

yese (审核中...)

前往app查看评论内容

#默沙东#

重磅新药！默沙东「来特莫韦片」在中国获批，用于巨细胞病毒的预防性治疗

2022-01-07

yese (审核中...)

前往app查看评论内容

#默沙东#

NEJM：默沙东ROR1 ADC展现淋巴瘤治疗的潜力

2021-11-30

yese (审核中...)

前往app查看评论内容

#默沙东#

跌破眼球！默沙东新冠病毒口服药有效率降至30%！

2021-11-28

yese (审核中...)

前往app查看评论内容

#默沙东#

英国批准默沙东新冠口服药物molnupiravir，开创新冠治疗的新时代！

2021-11-06

yese (审核中...)

前往app查看评论内容

#默沙东#

2021年10月26日简报：湖北、浙江、海南等地启动3-11岁人群新冠病毒疫苗接种；欧洲药品管理局开始滚动审查默沙东新冠口服药物

2021-10-27

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东治疗新冠肺炎口服特效药Molnupiravir取得良好效果，降低住院或死亡率50%，未来可能是治疗新冠的决定性药物之一

2021-10-04

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东以110亿美元收购Accelron接近完成，押注呼吸和血液疾病领域

2021-10-02

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东多拉韦林上市有望帮助HIV感染者应对血脂异常问题

2021-06-25

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东中国研发中心十年：守正出奇

2021-05-17

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东联合Surface开展联合疗法研究，或将改善K药耐药性

2021-04-05

yese (审核中...)

前往app查看评论内容

#默沙东#

HIV领域迎来强强联手，默沙东和吉利德合作开发长效方案

2021-04-05

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东在美国自主撤回Keytruda治疗转移性小细胞肺癌适应症

2021-03-09

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东收购华人研发新冠肺炎创新药物，有望成为新冠重症特效药物

2021-02-21

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东Keytruda治疗三阴性乳腺癌扩大标签申请未能获得FDA支持

2021-02-17

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东10亿美元豪掷T细胞接合剂免疫疗法（TCE）

2020-12-28

yese (审核中...)

前往app查看评论内容

#默沙东#

丁香园与默沙东等疫苗巨头共建疫苗服务平台正式布局“互联网+疫苗”领域

2020-12-07

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东HIV领域重磅新药沛卓（多拉韦林）在华获批，血脂控制获益显著

2020-12-05

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东多拉韦林在中国获批上市

2020-12-02

yese (审核中...)

前往app查看评论内容

#默沙东#

随着抗菌素耐药性加剧，默沙东的新型抗生素组合Recarbrio在英国上市

2020-11-21

科室
- - 订阅+
  - 更多科室
工具
服务